Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Flyte Aviation, Inc.RMED · Entity 8648 | Director | June 06, 2019 | June 07, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Flyte Aviation, Inc.
Report date June 06, 2019 · Filed June 07, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 70,475 |
Reported balance
After 2019-06-06 transaction · row 1
1 source rowRow 1 · 2019-06-06 · Grant · Acquired 29,850 · Balance 70,475 F1: Reported shares represents a grant of restricted stock units (the "RSUs") pursuant to Ra Medical Systems, Inc.'s 2018 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Ra Medical Systems, Inc. common stock. The RSUs will vest on the earlier of (i) June 6, 2020, or (ii) the day prior to the date of the Annual Meeting next following June 6, 2019, subject to the reporting person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: Reported shares represents a grant of restricted stock units (the "RSUs") pursuant to Ra Medical Systems, Inc.'s 2018 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Ra Medical Systems, Inc. common stock. The RSUs will vest on the earlier of (i) June 6, 2020, or (ii) the day prior to the date of the Annual Meeting next following June 6, 2019, subject to the reporting person's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 06, 2019 Filed Jun 7, 2019 17:42 UTC | Flyte Aviation, Inc. RMED · Entity 8648 | GrantCommon Stock | 29,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-035622 · doc4.xml · nonDerivative · entry 1 BUCHBINDER MAURICE · CIK 0001270178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,475 F1 · shares: Reported shares represents a grant of restricted stock units (the "RSUs") pursuant to Ra Medical Systems, Inc.'s 2018 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Ra Medical Systems, Inc. common stock. The RSUs will vest on the earlier of (i) June 6, 2020, or (ii) the day prior to the date of the Annual Meeting next following June 6, 2019, subject to the reporting person's continued service. Read SEC document |
| October 04, 2018 Filed Oct 5, 2018 18:11 UTC | Flyte Aviation, Inc. RMED · Entity 8648 | GrantCommon Stock | 8,235 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-054437 · doc4.xml · nonDerivative · entry 1 BUCHBINDER MAURICE · CIK 0001270178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,625 F1 · shares: Reported shares are represented by restricted stock units ("RSUs"), and each RSU is the economic equivalent of one share of Ra Medical Systems, Inc. common stock. 1/3rd of the RSUs shall vest annually beginning on October 4, 2019 such that the RSUs will be fully vested on October 4, 2021, subject to the reporting person's continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.